An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Irenic Welcomes the Appointment of a Shareholder Representative to Theravance Biopharma’s Board of Directors
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management
Believes Jim Kelly of Weiss Asset Management Will Bring Important Ownership Mentality to the Boardroom
Encourages the Board to Continue Taking Concrete Steps to Improve Capital Allocation, Enhance Corporate Governance and Review Strategic Alternatives
NEW YORK--(BUSINESS WIRE)--
Irenic Capital Management, LP (together with its affiliates, “Irenic” or “we”), a top shareholder of Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance” or the “Company”), today issued the following statement regarding the Company’s appointment of Jim Kelly, Managing Director at Weiss Asset Management, to the Board of Directors (the “Board”):
“Irenic welcomes the appointment of Jim Kelly to the Theravance Board. We respect and admire Jim’s investment acumen and thoughtfulness, and believe he brings a much-needed shareholder perspective to the boardroom. We are pleased the Theravance Board added him. The recent steps to increase the extent of the Company’s capital return program, modestly refresh the Board and submit a proposal to declassify the Board are steps in the direction of improved capital allocation and good governance.
We encourage the Board to: (1) Immediately announce a review of strategic alternatives; (2) accelerate the pace of the capital return program; and (3) make real the commitment to declassification by proposing to declassify immediately and by putting the directors up for election this year on a one-year term. Theravance has made progress. This is to be commended. We hope the Board finishes the job.”
About Irenic
Irenic Capital Management, LP is an investment management firm founded by Adam Katz and Andy Dodge. Based in New York City, Irenic works collaboratively with publicly traded companies to ensure operating activities, capital deployment and management incentives are all aligned to create value for the company and its owners. For more information about Irenic, please visit www.irenicmgmt.com.
theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
